Sodium-glucose cotransporter2 inhibitors in heart failure
DOI:
https://doi.org/10.56782/pps.240Keywords:
Inhibitors SGLT2, Heart failure, CardiologyAbstract
Heart failure (HF) is a serious problem in a modern world, with increasing prevalence among ageing populations. The use of sodium-glucose cotransporter2 (SGLT2) inhibitors, originally intended to treat type 2 diabetes, has revolutionised the treatment of HF. In this review article, we present the latest evidence on the mechanism of action of SGLT2 inhibitors, also called flosins, in HF. The primary mechanism of action of flosins is to reduce glucose reabsorption from glomerular filtration in the proximal renal tubule with a concomitant reduction in sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis. Based on experimental findings, several pleiotropic effects of SGLT2 inhibitors have been proposed. Mechanisms also include regulation of inflammatory and oxidative pathways along with improved endothelial function. Recent multicentre studies of SGLT2 inhibitors have shown that they reduce hospitalisations for heart failure after their use, regardless of type 2 diabetes and the degree of cardiac systolic dysfunction
Downloads
References
Savarese, G.; Becher, P.M.; Lund, L.H.; Seferovic, P.; Rosano, G.M.C.; Coats, A.J.S. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 2023, 118(17), 3272-3287. DOI:10.1093/cvr/cvac013 DOI: https://doi.org/10.1093/cvr/cvac013
Bleumink, G.S.; Knetsch, A.M.; Sturkenboom, M.C.; Straus, S.M.; Hofman, A.; Deckers, J.W.; Witteman, J.C.; Stricker, B.H. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur. Heart J. 2004, 25, 1614–1619. DOI: 10.1016/j.ehj.2004.06.038 DOI: https://doi.org/10.1016/j.ehj.2004.06.038
Imprialos, K.; Stavropoulos, K.; Papademetriou, V. Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Fail. Clin. 2019, 15(4), 519-530. DOI: 10.1016/j.hfc.2019.06.004 DOI: https://doi.org/10.1016/j.hfc.2019.06.004
Nessler, J.; Kozierkiewicz, A.; Gackowski, A.; Ponikowski, P.; Hryniewiecki, T.; Grucha-ła, M.; Gąsior, M.; Grodzicki, T.; Kaźmierczak, J.; Legutko, J.; Leszek, P.; Miłkowski, M.; Rozen-Tryt, P.; Sierpiński, R.; Straburzyńska -Migaj, E.; Śliwczyński, A.; Uchmanowicz, I.; Windak, A.; Witkowski, A.; Zapaśnik, A.; Szumowski, Ł. Comprehensive Heart Failure Care pilot study: starting point and expected developments. Kardiol. Pol. 2019, 77, 994–999. DOI: 10.33963/KP.15035 DOI: https://doi.org/10.33963/KP.15035
Lopuszynski, J.B.; Downing, A.J.; Finley, C.M.; Zahid, M. Prognosticators of All-Cause Mortality in Patients With Heart Failure With Preserved Ejection Fraction. Am. J. Cardiol. 2021, 1(158), 66-73. DOI: 10.1016/j.amjcard.2021.07.044 DOI: https://doi.org/10.1016/j.amjcard.2021.07.044
Maggioni, AP.; Dahlström, U.; Filippatos, G.; Chioncel, O.; Crespo Leiro, M.; Drozdz, J.; Fruhwald, F.; Gullestad, L.; Logeart, D.; Fabbri, G.; Urso, R.; Metra, M.; Parissis, J.; Pers-son, H.; Ponikowski, P.; Rauchhaus, M.; Voors, A.A.; Nielsen, O.W.; Zannad, F.; Tavazzi, L. He-art Failure Association of the European Society of Cardiology (HFA). EURObserva-tional Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot). Eur. J. Heart Fail. 2013, 15, 808–817. DOI: 10.1093/eurjhf/hft050 DOI: https://doi.org/10.1093/eurjhf/hft050
Murphy, S.P.; Ibrahim, N.E.; Januzzi, J.L. Heart Failure With Reduced Ejection Fraction: A Review. JAMA 2020, 324(5), 488–504. DOI:10.1001/jama.2020.10262 DOI: https://doi.org/10.1001/jama.2020.10262
Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; González -Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; Jessup, M.; Linde, C.; Nihoyannopo-ulos, P.; Parissis, J.T.; Pieske, B.; Riley, J.P.; Rosano, G.M.; Ruilope, L.M.; Ruschitzka, F.; Rutten, F.H.; van der Meer, P. Wytyczne ESC dotyczace diagnostyki i leczenia ostrej i przewle-kłej niewydolności serca w 2016 roku. Kardiol. Pol. 2016, 74, 1037–1147. DOI: 10.5603/KP.2016.0141 DOI: https://doi.org/10.5603/KP.2016.0141
Wright, E.M. SGLT2 Inhibitors: Physiology and Pharmacology. Kidney 360. 2021, 17, 2(12), 2027-2037. DOI: 10.34067/KID.0002772021. DOI: https://doi.org/10.34067/KID.0002772021
Vallon, V.; Thomson, SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017, 60(2), 215-225. DOI: 10.1007/s00125-016-4157-3 DOI: https://doi.org/10.1007/s00125-016-4157-3
Packer, M.; Anker, S. D.; Butler, J.; Filippatos, G.; Ferreira, J. P.; Pocock, S. J.; Sattar, N.; Brueckmann, M.; Jamal, W.; Cotton, D.; Iwata, T.; Zannad, F. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J. Am. Coll. Cardiol. 2021, 77, 1381–1392. DOI: 10.1016/j.jacc.2021.01.033 DOI: https://doi.org/10.1016/j.jacc.2021.01.033
Chilton, R.; Tikkanen, I.; Cannon, C. P.; Crowe, S.; Woerle, H. J.; Broedl, U. C.; Johansen, O. E. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab. 2015, 17, 1180–1193. DOI: 10.1111/dom.12572 DOI: https://doi.org/10.1111/dom.12572
Solini, A.; Giannini, L.; Seghieri, M.; Vitolo, E.; Taddei, S.; Ghiadoni, L.; Bruno, R.M. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc. Diabetol. 2017, 16, 138. DOI: 10.1186/s12933-017-0621-8 DOI: https://doi.org/10.1186/s12933-017-0621-8
Aroor, A. R.; Das, N. A.; Carpenter, A. J.; Habibi, J.; Jia, G.; Ramirez-Perez, F. I.; Martinez-Lemus, L.; Manrique-Acevedo, C. M.; Hayden, M. R.; Duta, C.; Nistala, R.; Mayoux, E.; Padilla, J.; Chandrasekar, B.; DeMarco, V. G. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc. Diabetol. 2018, 17, 108. DOI: 10.1186/s12933-018-0750-8 DOI: https://doi.org/10.1186/s12933-018-0750-8
Mahaffey, KW.; Jardine, M.J.; Bompoint, S.; Cannon, C.P.; Neal, B.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Capuano, G.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Sun, T.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Rosenthal, N.; Brenner, B.M.; Perkovic, V. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation 2019, 27, 140(9), 739-750. DOI: 10.1161/CIRCULATIONAHA.119.042007 DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042007
Nielsen, R.; Møller, N.; Gormsen, L.C.; Tolbod, L.P.; Hansson, N.H.; Sorensen, J.; Harms, H.J.; Frøkiær, J.; Eiskjaer, H.; Jespersen, N.R.; Mellemkjaer, S.; Lassen, T.R.; Pryds, K.; Bøtker, H.E.; Wiggers, H. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation 2019, 30, 139(18), 2129-2141. DOI: 10.1161/CIRCULATIONAHA.118.036459 DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.036459
Lopaschuk, G.D.; Verma, S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl. Sci. 2020, 5, 632–644. DOI: 10.1016/j.jacbts.2020.02.004 DOI: https://doi.org/10.1016/j.jacbts.2020.02.004
Vaduganathan, M.; Docherty, K.F.; Claggett, B.L.; Jhund, P.S.; de Boer, R.A.; Hernandez, A.F.; Inzucchi, S.E.; Kosiborod, M.N.; Lam, C.S.P.; Martinez, F.; Shah, S.J.; Desai, A.S.; McMurray, J.J.V.; Solomon, S.D. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022, 400(10354), 757-767. DOI: 10.1016/S0140-6736(22)01429-5 DOI: https://doi.org/10.1016/S0140-6736(22)01429-5
Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; Benetos, A.;, Biffi, A.; Boavida, J.M.; Capodanno, D.; Cosyns, B.; Crawford, C.; Davos, C.H.; Desormais, I.; Di Angelantonio, E.; Franco, O.H.; Halvorsen, S.; Hobbs, F.D.R.; Hollander, M.; Jankowska, E.A.; Michal, M.; Sacco, S.; Sattar, N.; Tokgozoglu, L.; Tonstad, S.; Tsioufis, K.P.; van Dis, I.; van Gelder, I.C.; Wanner, C.; Williams, B. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021, 42(34), 3227-3337. doi: 10.1093/eurheartj/ehab484 Erratum in: Eur. Heart J. 2022, 43(42), 4468-4468. DOI: 10.1093/eurheartj/ehac458 DOI: https://doi.org/10.1093/eurheartj/ehac458
Santos-Gallego, C.G.; Vargas-Delgado, A.P.; Requena-Ibanez, J.A.; Garcia-Ropero, A.; Mancini, D.; Pinney, S.; Macaluso, F.; Sartori, S.; Roque, M.; Sabatel-Perez, F.; Rodriguez-Cordero, A.; Zafar, M.U.; Fergus, I.; Atallah-Lajam, F.; Contreras, J.P.; Varley, C.; Moreno, P.R.; Abascal, V.M.; Lala, A.; Tamler, R.; Sanz, J.; Fuster, V.; Badimon, J.J. EMPA-TROPISM (ATRU-4) Investigators. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J. Am. Coll. Cardiol. 2021, 26, 77(3), 243-255. DOI: 10.1016/j.jacc.2020.11.008 DOI: https://doi.org/10.1016/j.jacc.2020.11.008
Packer, M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation 2022, 146, 1383–1405. DOI: 10.1161/CIRCULATIONAHA.122.061732 DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.061732
Benham, J.L.; Booth, J.E.; Sigal, R.J.; Daskalopoulou, S.S.; Leung, A.A.; Rabi, D.M. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int. J. Cardiol. Heart Vasc. 2021, 10(33), Art. No: 100725. DOI: 10.1016/j.ijcha.2021.100725 DOI: https://doi.org/10.1016/j.ijcha.2021.100725
Bedi, K.C.Jr.; Snyder, N.W.; Brandimarto, J.; Aziz, M.; Mesaros, C.; Worth, A.J.; Wang, L.L.; Javaheri, A.; Blair, I.A.; Margulies, K.B.; Rame, J.E. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation 2016, 133(8), 706-16. DOI: 10.1161/CIRCULATIONAHA.115.017545 DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.017545
Scheen, A.J. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr. Cardiol. Rep. 2019, 21, Art. No: 70. DOI: 10.1007/s11886-019-1165-1 DOI: https://doi.org/10.1007/s11886-019-1165-1
Wang, J.; Chen, Y.; Xu, W.; Lu, N.; Cao, J.; Yu, S. Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. PLoS One 2019, 14(4), e0215362. DOI: 10.1371/journal.pone.0215362 DOI: https://doi.org/10.1371/journal.pone.0215362
Heymans, S.; Hirsch, E.; Anker, S.D.; Aukrust, P.; Balligand, J.L.; Cohen-Tervaert, J.W.; Drexler, H.; Filippatos, G.; Felix, S.B.; Gullestad, L.; Hilfiker-Kleiner, D.; Janssens, S.; Latini, R.; Neubauer, G.; Paulus, W.J.; Pieske, B.; Ponikowski, P.; Schroen, B.; Schultheiss, H.P.; Tschöpe, C.; Van Bilsen, M.; Zannad, F.; McMurray, J.; Shah, A.M. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2009, 11(2), 119-29. DOI: 10.1093/eurjhf/hfn043 DOI: https://doi.org/10.1093/eurjhf/hfn043
Kolijn, D.; Pabel, S.; Tian, Y.; Lódi, M.; Herwig, M.; Carrizzo, A.; Zhazykbayeva, S.; Kovács, Á.; Fülöp, G.Á.; Falcão-Pires, I.; Reusch, P.H.; Linthout, S.V.; Papp, Z.; van Heerebeek, L.; Vecchione, C.; Maier, L.S.; Ciccarelli, M.; Tschöpe, C.; Mügge, A.; Bagi, Z.; Sossalla, S.; Hamdani, N. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc. Res. 2021, 117(2), 495-507. DOI: 10.1093/cvr/cvaa123 DOI: https://doi.org/10.1093/cvr/cvaa123
Bray, J.J.H.; Foster-Davies, H.; Stephens, J.W. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res. Clin. Pract. 2020, 168, Art. No: 108368. DOI: 10.1016/j.diabres.2020.108368 DOI: https://doi.org/10.1016/j.diabres.2020.108368
Nabrdalik-Leśniak, D.; Nabrdalik, K.; Sedlaczek, K.; Główczyński, P.; Kwiendacz, H.; Sawczyn, T.; Hajzler, W.; Drożdż, K.; Hendel, M.; Irlik, K.; Stelmach, P.; Adamczyk, P.; Paradysz, A.; Kasperczyk, S.; Stompór, T.; Gumprecht, J. Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study. Oxid. Med. Cell Longev. 2021, 2021, Art. No: 5593589. DOI: 10.1155/2021/5593589 DOI: https://doi.org/10.1155/2021/5593589
Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006, 444, 860–867. DOI: 10.1038/nature05485 DOI: https://doi.org/10.1038/nature05485
Garvey, W.T.; Van Gaal, L.; Leiter, L.A.; Vijapurkar, U.; List, J.; Cuddihy, R.; Ren, J.; Davies, M.J. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018, 85, 32-37. DOI: 10.1016/j.metabol.2018.02.002 DOI: https://doi.org/10.1016/j.metabol.2018.02.002
Braga, T. T.; Forni, M. F.; Correa-Costa, M.; Ramos, R. N.; Barbuto, J. A.; Branco, P.; Castoldi, A.; Hiyane, M. I.; Davanso, M. R.; Latz, E.; Franklin, B. S.; Kowaltowski, A. J.; Camara, N. O. Soluble uric acid activates the NLRP3 inflammasome. Sci. Rep. 2017, 7, Art. No: 39884. DOI: 10.1038/srep39884 DOI: https://doi.org/10.1038/srep39884
Kim, S.R.; Lee, S.G.; Kim, S.H.; Kim, J.H.; Choi, E.; Cho, W.; Rim, J.H.; Hwang, I.; Lee, C.J.; Lee, M.; Oh, C.M.; Jeon, J.Y.; Gee, H.Y.; Kim, J.H.; Lee, B.W.; Kang, E.S.; Cha, B.S.; Lee, M.S.; Yu, J.W.; Cho, J.W.; Kim, J.S.; Lee, Y.H. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 2020, 11(1), Art. No: 2127. DOI: 10.1038/s41467-020-15983-6 DOI: https://doi.org/10.1038/s41467-020-15983-6
Lee, T.M.; Chang, N.C.; Lin, S.Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 2017, 104, 298–310. DOI: 10.1016/j.freeradbiomed.2017.01.035 DOI: https://doi.org/10.1016/j.freeradbiomed.2017.01.035
Li, C.; Zhang, J.; Xue, M.; Li, X.; Han, F.; Liu, X.; Xu, L.; Lu, Y.; Cheng, Y.; Li, T.; Yu, X.; Sun, B.; Chen, L. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol. 2019, 18(1), Art. No: 15. DOI: 10.1186/s12933-019-0816-2 DOI: https://doi.org/10.1186/s12933-019-0816-2
Kang, S.; Verma, S.; Hassanabad, A.F.; Teng, G.; Belke, D.D.;Dundas, J.A.; Guzzardi, D.G.; Svystonyuk, D.A.; Pattar, S.S.; Park, D.S.J.; Turnbull, J.D.; Duff, H.J.; Tibbles, L.A.; Cunnington, R.H.; Dyck, J.R.B.; Fedak, P.W.M. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can. J. Cardiol. 2020, 36(4), 543-553. DOI: 10.1016/j.cjca.2019.08.033. DOI: https://doi.org/10.1016/j.cjca.2019.08.033
Verma, S.; Mazer, C. D.; Yan, A. T.; Mason, T.; Garg, V.; Teoh, H.; Zuo, F.; Quan, A.; Farkouh, M. E.;, Fitchett, D. H.; Goodman, S. G.; Goldenberg, R. M.; Al-Omran, M.; Gilbert, R. E.; Bhatt, D. L.; Leiter, L. A.; Jüni, P.; Zinman, B.; Connelly, K. A. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 2019, 140, 1693–1836. DOI: 10.1161/CIRCULATIONAHA.119.042375 DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042375
Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; GerasimosFilippatos, G.; Diederick, E.; Grobbee, D.E.; Hansen, T.B.; Huikuri, H.V.; Johans-son, I.; Jüni, P.; Lettino, M.; Marx, N.; Mellbin, L.G.; Östgren, C.J.; Rocca, B.; Roffi, M.; Sattar, N.; Seferović, P.M.; Sousa -Uva, M.; Valensi, P.; Wheeler, DC. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020, 41(2), 255–323. DOI: 10.1093/eurheartj/ehz486 DOI: https://doi.org/10.1093/eurheartj/ehz486
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. EMPA -REG OUTCOME In-vestigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015, 373, 2117–2128. DOI: 10.1056/NEJMoa1504720. DOI: https://doi.org/10.1056/NEJMoa1504720
Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. CANVAS Program Collaborative Group. Canagli-flozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017, 377, 644–657. DOI: 10.1056/NEJMoa1611925. DOI: https://doi.org/10.1056/NEJMoa1611925
Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Ruff, C.T.; Gause -Nilsson, I.A.M.; Fredriksson, M.; Johansson, P.A.; Langkilde, A.M.; Sabatine, M.S. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019, 380, 347–357. DOI: 10.1056/NEJMoa1812389. DOI: https://doi.org/10.1056/NEJMoa1812389
Wanner. C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B. EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 2016, 375(4), 323-34. DOI: 10.1056/NEJMoa1515920. DOI: https://doi.org/10.1056/NEJMoa1515920
Furtado, R.H.M.; Bonaca, M.P.; Raz, I.; Zelniker, T.A.; Mosenzon, O.; Cahn, A.; Kuder, J.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Ruff, C.T.; Nicolau, J.C.; Gause-Nilsson, I.A.M.; Fredriksson, M.; Langkilde, A.M.; Sabatine, M.S.; Wiviott, S.D. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation 2019, 139(22), 2516-2527. DOI: 10.1161/CIRCULATIONAHA.119.039996 DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.039996
Zelniker, T.A.; Wiviott, S.D.; Raz, I.; Im, K.; Goodrich, E.L.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Furtado, R.H.M.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Sabatine, M.S. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019, 393(10166), Art. No: 30. DOI: 10.1016/S0140-6736(18)33206-9 DOI: https://doi.org/10.1016/S0140-6736(18)32590-X
Inzucchi, S.E.; Kosiborod, M.; Fitchett, D.; Wanner, C.; Hehnke, U.; Kaspers, S.; George, J.T.; Zinman, B. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. Circulation. 2018, 138(17), 1904-1907. DOI: 10.1161/CIRCULATIONAHA.118.035759 DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.035759
Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl. J. Med. 2019, 380(24), 2295-2306. DOI: 10.1056/NEJMoa1811744 DOI: https://doi.org/10.1056/NEJMoa1811744
McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; Böhm, M.; Chiang, C.E.; Chopra, V.K.; de Boer, R.A.; Desai, A.S.; Diez, M.; Drozdz, J.; Dukát, A.; Ge, J.; Howlett, J.G.; Katova, T.; Kitakaze, M.; Ljungman, C.E.A.; Merkely, B.; Nicolau, J.C.; O'Meara, E.; Petrie, M.C.; Vinh, P.N.; Schou, M.; Tereshchenko, S.; Verma, S.; Held, C.; DeMets, D.L.; Docherty, K.F.; Jhund, P.S.; Bengtsson, O.; Sjöstrand, M.; Langkilde, A.M. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019, 381(21), 1995-2008. DOI: 10.1056/NEJMoa1911303 DOI: https://doi.org/10.1056/NEJMoa1911303
Packer, M.; Anker, S.D.; Butler, J. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation 2021, 143, 326-336. DOI: 10.1161/CIRCULATIONAHA.120.051783 DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.051783
Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; Jamal, W.; Kimura, K.; Schnee, J.; Zeller, C.; Cotton, D.; Bocchi, E.; Böhm, M.; Choi, D.-J.; Chopra, V.; Chuquiure, E.; Giannetti, N.; Janssens, S.; Zhang, J.; Gonzalez Juanatey, J.R.; Kaul, S.; Brunner-La Rocca, H.-P.; Merkely, B.; Nicholls, S.J.; Perrone, S.; Pina, I.; Ponikowski, P.; Sattar, N.; Senni, M.; Seronde, M.-F.; Spinar, J.; Squire, I.; Taddei, S.; Wanner, .; Zannad, F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 2020, 383, 1413–1424. DOI: 10.1056/NEJMoa2022190 DOI: https://doi.org/10.1056/NEJMoa2022190
McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; Cleland, J.G.F.; Coats, A.J.S.; Crespo-Leiro, M.G.; Farmakis, D.; Gilard, M.; Heymans, S.; Hoes, A.W.; Jaarsma, T.; Jankowska, E.A.; Lainscak, M.; Lam, C.S.P.; Lyon, A.R.; McMurray, J.J.V.; Mebazaa, A.; Mindham, R.; Muneretto, C.; Francesco Piepoli, M.; Price, S.; Rosano, G.M.C.; Ruschitzka, F.; Kathrine Skibelund, A. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42(48), 4901. DOI: 10.1093/eurheartj/ehab670 DOI: https://doi.org/10.1093/eurheartj/ehab670
Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Böhm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; Giannetti, N.; Gomez-Mesa, J.E.; Janssens, S.; Januzzi, J.L.; Gonzalez-Juanatey J.R.; Merkely, B.; Nicholls, S.J.; Perrone, S.V.; Piña, I.L.; Ponikowski, P.; Senni, M.; Sim, D.; Spinar, J.; Squire, I.; Taddei, S.; Tsutsui, H.; Verma, S.; Vinereanu, D.; Zhang, J.; Carson, P.; Lam, C.S.P.; Marx, N.; Zeller, C.; Sattar, N.; Jamal, W.; Schnaidt, S.; Schnee, J.M.; Brueckmann, M.; Pocock, S.J.; Zannad, F.; Packer, M. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med. 2021, 385(16), 1451-1461. DOI: 10.1056/NEJMoa2107038 DOI: https://doi.org/10.1056/NEJMoa2107038
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Wojciech Kaźmierski, Jakub Jurek, Paulina Lis, Anna Lis, Anna Ziobro, Mateusz Ziomek, Katarzyna Camlet, Kinga Kocur
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
